Here is the news that was sent out the market was closed. Hope it will give a push of the stock tommorow.
Monday January 6 4:22 PM EDT
ImmuLogic Files Investigational New Drug Application with the
FDA for Multiple Sclerosis Therapeutic
WALTHAM, Mass., Jan. 6 /PRNewswire/ -- Immulogic Pharmaceutical Corp today announced the filing of an
investigational new drug (IND) application with the Food and Drug Administration to initiate human clinical trials for
a multiple sclerosis peptide therapeutic.
"This IND was filed in preparation for a phase I trial we plan to initiate in the second quarter of 1997, following the
completion of final manufacturing processes for the clinical grade product to be used in the trial," said Joseph Marr,
MD, Acting President and Chief Executive Officer of ImmuLogic Pharmaceutical Corporation. "This IND filing is
our first step in expanding the clinical application of our core technology of tolerance induction beyond allergy and
into the autoimmune disease arena. The autoimmune patient groups have a significant need for novel therapeutics that
we hope to address with products from our program."
Although significant advances in the therapeutic management of multiple sclerosis have been made, there is an
additional need for products which specifically address the underlying cause of the disease. The ImmuLogic
therapeutic is aimed at turning off the T cells which trigger the inflammatory response that destroys the myelin sheath
surrounding nerves. ImmuLogic's multiple sclerosis peptide therapeutic consists of myelin basic protein peptides
administered by subcutaneous injection. The company is developing its multiple sclerosis program in collaboration
with Schering AG, Germany, a world leader in the multiple sclerosis disease management field.
ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company, located in Waltham, Massachusetts, with
the primary goal of developing peptide therapeutics to treat allergies and autoimmine diseases. The Company also is
developing a poison ivy/poison oak therapeutic and a vaccine to treat cocaine abuse. SOURCE ImmuLogic
Pharmaceutical Corporation |
